Skip to content
DataLookout
Menu

Regeneron Pharmaceuticals clinical trial pipeline

Get alerts when Regeneron Pharmaceuticals's trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-08

What changed in the last 30 days

29 trials changed in the last 30 days: 0 stopped, 5 with notable changes, 24 with minor changes only.

  1. Minor: ACCESS-1 · How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works · Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment Trial completed Regeneron PharmaceuticalsPhase 3 NCT05133531
  2. Minor: LINKER-MM4 · Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works · Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment Enrollment closed, study ongoing Regeneron PharmaceuticalsPhase 1/2 NCT05828511
  3. Minor: AURA-AD · REGN20423 in Healthy Adult Participants and Adult · Atopic Dermatitis Primary and study completion pushed from Jun 23, 2028 to Aug 14, 2028 Regeneron PharmaceuticalsPhase 1 NCT07527923
  4. Minor: Ubamatamab Combination Therapy · Platinum-Resistant Ovarian Cancer Enrollment increased: 297 → 397 participants Regeneron PharmaceuticalsPhase 2 NCT06787612
  5. Minor: ROXI-ASPEN · REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants Trial sites expanded: 49 → 57 locations Regeneron PharmaceuticalsPhase 3 NCT07213778
  6. Minor: ROXI-PALISADE · Reducing Adverse Vascular Outcomes With Factor XI Inhibition · Peripheral Artery Disease Trial sites expanded: 29 → 32 locations Regeneron PharmaceuticalsPhase 3 NCT07318610
  7. Minor: ROXI-CAT-I · REGN7508 in Adult Participants · Cancer-Associated Thrombosis Trial sites expanded: 23 → 28 locations Regeneron PharmaceuticalsPhase 3 NCT07410117
  8. Minor: ROXI-EVEREST · Stroke and Systemic Embolism Prevention · Atrial Fibrillation Trial sites expanded: 54 → 66 locations Regeneron PharmaceuticalsPhase 3 NCT07626411
  9. Minor: ROXI-ATLAS · Adult · Atrial Fibrillation Who Are Treated With Anticoagulation Trial sites expanded: 87 → 91 locations Regeneron PharmaceuticalsPhase 2 NCT07175428
  10. Minor: ALN-CIDEB · Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH) Enrollment closed, study ongoing Regeneron PharmaceuticalsPhase 1/2 NCT06836609
  11. Minor: LINKER-MM5 · Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens · Relapsed/Refractory Multiple Myeloma (RRMM) Trial sites expanded: 44 → 53 locations Regeneron PharmaceuticalsPhase 3 NCT07222761
  12. Minor: LINKER-SMM2 · Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM) Trial sites expanded: 27 → 33 locations Regeneron PharmaceuticalsPhase 3 NCT07393282
  13. Minor: Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab · Metastatic Castration-Resistant Prostate Cancer and Other Tumors Trial sites expanded: 24 → 27 locations Regeneron PharmaceuticalsPhase 1/2 NCT03972657
  14. Notable: Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments · Operable Non-Small Cell Lung Cancer (NSCLC) Primary completion pushed from May 20, 2027 to Dec 4, 2029 Regeneron PharmaceuticalsPhase 2 NCT06465329
  15. Minor: Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD) Trial completed Regeneron PharmaceuticalsPhase 3 NCT02612454
  16. Notable: ALN-CIDEB · Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Recruitment opened Regeneron PharmaceuticalsPhase 3 NCT07854782
  17. Minor: CEMI-LUNG · Cemiplimab · Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe Enrollment closed, study ongoing Regeneron PharmaceuticalsNot specified NCT05363319
  18. Minor: Cemiplimab-based Treatments · Locally Advanced Basal Cell Skin Cancer (laBCC) Start date pushed from Oct 15, 2026 to Nov 13, 2026 Regeneron PharmaceuticalsPhase 2 NCT07808515
  19. Notable: REGN17235 · Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation Recruitment opened Regeneron PharmaceuticalsPhase 1 NCT07753148
  20. Notable: ALN-CIDEB · Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Recruitment opened Regeneron PharmaceuticalsPhase 2 NCT07631637
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

New trial filings, last 30 days

First postedTrialPhaseStatus
2026-10-28 NCT07901725 Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone… Phase 3 Not Yet Recruiting
2026-10-26 NCT07896265 Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without Diabetes Phase 3 Not Yet Recruiting
2026-10-21 NCT07887750 REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or… Phase 1/2 Not Yet Recruiting
2026-10-15 NCT07876492 A Study to Evaluate Cenvacibart (REGN7508) for Secondary Stroke Prevention in Adult… Phase 3 Not Yet Recruiting
2026-10-15 NCT07876505 Healthy Adult Participants Trial Comparing Different Cenvacibart Presentations Phase 1 Not Yet Recruiting

Active trials by phase

Phase 1
18
Phase 1/2
26
Phase 2
27
Phase 2/3
2
Phase 3
36
Phase 4
4
Not charted: 10 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Disease areas by active trials, top 10 of 39

Get alerts when Regeneron Pharmaceuticals's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free